Michel Langlois
Overview
Explore the profile of Michel Langlois including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cavalier E, Zima T, Datta P, Makris K, Schaeffner E, Langlois M, et al.
Clin Chem Lab Med
. 2024 Nov;
63(3):525-534.
PMID: 39584585
The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for chronic kidney disease (CKD) evaluation and management bring important updates, particularly for European laboratories. These guidelines emphasize the need for...
2.
Delanaye P, Schaeffner E, Cozzolino M, Langlois M, Plebani M, Ozben T, et al.
Clin Chem Lab Med
. 2022 Oct;
61(1):44-47.
PMID: 36279207
The EFLM recommends not to implement the race-free Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation in European laboratories and to keep the 2009 version of the CKD-EPI equation, without applying...
3.
Delayed diagnosis and treatment of extreme hypertriglyceridemia due to rejection of a lipemic sample
Van Elslande J, Hijjit S, De Vusser K, Langlois M, Meijers B, Mertens A, et al.
Biochem Med (Zagreb)
. 2021 Apr;
31(2):021002.
PMID: 33927560
Introduction: Most laboratories routinely determine haemolysis, icterus and lipemia indices to identify lipemic samples and reject potentially affected results. Hypertriglyceridemia is the most common cause of lipemia and severe hypertriglyceridemia...
4.
Sniderman A, Langlois M, Cobbaert C
Curr Opin Lipidol
. 2021 Apr;
32(4):226-230.
PMID: 33870931
Purpose Of Review: The 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines concluded that apolipoprotein B (apoB) was a more accurate measure of cardiovascular risk and a better guide to...
5.
Descamps O, Verhaegen A, Demeure F, Langlois M, Rietzschel E, Mertens A, et al.
Acta Clin Belg
. 2019 Dec;
75(1):80-90.
PMID: 31846601
It has been well established that low-density lipoproteins (LDL) and other apolipoprotein B-containing lipoproteins are causally related to atherosclerotic cardiovascular disease (ASCVD) and that lowering these lipoproteins reduces the risk...
6.
Descamps O, Van Caenegem O, Hermans M, Balligand J, Beauloye C, Bondue A, et al.
Atherosclerosis
. 2018 Oct;
277:369-376.
PMID: 30270073
Background And Aims: Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein disorder characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly increased risk of premature cardiovascular disease (CVD)....
7.
Banach M, Patti A, Giglio R, Cicero A, Atanasov A, Bajraktari G, et al.
J Am Coll Cardiol
. 2018 Jun;
72(1):96-118.
PMID: 29957236
Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such...
8.
9.
Cicero A, Colletti A, Bajraktari G, Descamps O, Djuric D, Ezhov M, et al.
Nutr Rev
. 2017 Sep;
75(9):731-767.
PMID: 28938795
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals...
10.
Cicero A, Colletti A, Bajraktari G, Descamps O, Djuric D, Ezhov M, et al.
Arch Med Sci
. 2017 Sep;
13(5):965-1005.
PMID: 28883839
No abstract available.